Results 101 to 110 of about 11,186 (206)

Tolerability of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults.

, 2006
OBJECTIVE: To assess the tolerability and efficacy of amodiaquine (AQ)+sulphadoxine-pyrimethamine (SP), the first-line malaria treatment in Rwanda. METHOD: Randomized, double-blind trial in 2003 in Kigali town.
Karema, Corine, D'Alessandro, U., Fanello, C. I., van Doren, W., Rwagacondo, C. E., van Doren, W, Karema, C., Fanello, Caterina I, D'Alessandro, Umberto, Fanello, CI, van Doren, Walli, D'Alessandro, U, Karema, C, Rwagacondo, CE, Rwagacondo, Claude E   +14 more
core   +1 more source

A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda.

, 2006
Coartem is a fixed-dose combination of artemether-lumefantrine that, given in six doses, provides effective treatment for children with uncomplicated Plasmodium falciparum infection in areas with highly endemic and multidrug-resistant malaria.
Ngamije, D., D'Alessandro, U., Ngamije, D, Fanello, C. I., van Doren, W, van Doren, W., Karema, C., Van Overmeir, C, Fanello, CI, Van Overmeir, C., Van Overmeir, Chantal, D'Alessandro, U, Karema, C   +12 more
core   +1 more source

Dihydroartemisinin restores the immunogenicity and enhances the anticancer immunosurveillance of cisplatin by activating the PERK/eIF2α pathway

Cell & Bioscience
Background Immunosurveillance is pivotal in the effectiveness of anticancer therapies and tumor control. The ineffectiveness of cisplatin in activating the immunosurveillance is attributed to its lack of adjuvanticity resulting from its inability to ...
Yumei Li, Pei Ma, Jingxia Li, Feng Wu, Mengfei Guo, E Zhou, Siwei Song, Sufei Wang, Shuai Zhang, Yang Jin   +9 more
doaj   +1 more source

NANOPARTICLE-BASED formulation of dihydroartemisinin-lumefantrine duo-drugs: Preclinical Evaluation and enhanced antimalarial efficacy in a mouse model

Heliyon
Artemisinin-based combinations (ACTs) are World Health Organization-recommended treatment for malaria. Artemether (A) and lumefantrine (LUM) were the first co-formulated ACT and first-line treatment for malaria globally, artemether is dihydroartemisinin ...
Pesila Akeyo Odera, Geoffrey Otieno, Joab Otieno Onyango, James Jorum Owuor, Florence Anyango Oloo, Martin Ongas, Jeremiah Gathirwa, Bernhards Ogutu   +7 more
doaj   +1 more source

Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine

Malaria Journal, 2010
Background Artemether-lumefantrine is one of the most widely used anti-malarial drug combinations in the world with excellent tolerability and cure rates in adult and paediatric patients with uncomplicated falciparum malaria. The aim of this study was to
Tarning Joel, Najmi Muzammil H, Ali Shabana, Lindegardh Niklas   +3 more
doaj   +1 more source

The World Bank: false financial and statistical accounts and medical malpractice in malaria treatment.

, 2006
and is the largest organisation operating with a mission to reduce poverty worldwide. Malaria destroys about 1 million lives a year; the disease is the leading parasitic cause of death for Africa’s children and impoverishment for their families.
Sibley, CH, Mutabingwa, Theonest K., d'Alessandro, U, Watkins, WM, Fanello, CI, Garett, L., Talisuna, A., Attaran, Amir, D'Alessandro, U., Mutabingwa, TK, d'Alessandro, Umberto, Fanello, Caterina I, Sibley, Carol Hopkins, Barnes, K. I., Hopkins Sibley, C., Attaran, A, Roger Bate, Garrett, Laurie, Carol Hopkins Sibley, Bate, R, William M Watkins, Laurie Garrett, Watkins, William M., Watkins, William M, Fanello, C. I., Roberts, D, Amir Attaran, Garrett, L, Barnes, KI, d' Alessandro, Umberto, Barnes, Karen I., Ambrose Talisuna, Mutabingwa, Theonest K, Bate, Roger, Donald Roberts, Talisuna, Ambrose, Fanello, Caterina, Watkins, W. M., Jean-pierre Van Geertruyden, Van Geertruyden, J. P., Karen I Barnes, Theonest K Mutabingwa, Mutabingwa, T. K., Van Geertruyden, JP, Barnes, Karen I, Talisuna, A, Fred Binka, Roberts, D., Binka, Fred, Binka, F, Binka, F., Van Geertruyden, Jean-Pierre, Roberts, Donald, Attaran, A., Caterina I Fanello, Bate, R.   +55 more
core   +1 more source

A randomised trial to assess the efficacy and safety of chlorproguanil/dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria.

, 2008
We tested the efficacy and safety of chlorproguanil/dapsone co-administered with artesunate (CD+A) for the treatment of uncomplicated Plasmodium falciparum malaria in children compared with amodiaquine+sulfadoxine/pyrimethamine (AQ+SP) at two different ...
Ngamije, D., D'Alessandro, U., Ngamije, D, Fanello, C. I., Karema, C., Van Doren, W., Ndahindwa, V, Uwimana, A, Van Overmeir, C, Uwimana, A., Fanello, CI, Van Doren, W, Van Overmeir, C., Ndahindwa, V., D'Alessandro, U, Curtis, J., Karema, C, Curtis, J   +17 more
core   +1 more source

Corrigendum: Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma

Frontiers in Oncology, 2021
Ying Chen, Ying Chen, Rui Li, Yuqi Zhu, Yuqi Zhu, Sixia Zhong, Jinjun Qian, Dongqing Yang, Artur Jurczyszyn, Meral Beksac, Chunyan Gu, Chunyan Gu, Ye Yang, Ye Yang   +13 more
doaj   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Nanoscale dihydroartemisinin@zeolitic imidazolate frameworks for enhanced antigiardial activity and mechanism analysis

Frontiers in Veterinary Science
An artificial semisynthetic material can be derived from artemisinin (ART) called dihydroartemisinin (DHA). Although DHA has enhanced antigiardial potential, its clinical application is limited because of its poor selectivity and low solubility. The drug’
Xiaoming Jiang, Yawei Li, Shuainan Liu, Hongyu Sun, Meiyu Zheng, Xi Wan, Wenhe Zhu, Xianmin Feng, Xianmin Feng   +8 more
doaj   +1 more source